Literature DB >> 28512405

Concomitant B Hairy Cell Leukemia and Mycosis Fungoides in an Elderly Man.

Eric Wong1, Muhammad N Mahmood2, Thomas G Salopek1.   

Abstract

The development of both a T- and B-cell lymphoproliferative disorder in one patient is an unlikely coincidence due to the low prevalence of each malignancy. We report a 65-year-old man with a previously documented history of B hairy cell leukemia, who presented with a new-onset acneiform eruption of his scalp, face, trunk, back, and extremities. Routine pathology of the skin lesions with immunohistochemical stains and molecular studies were consistent with a folliculotropic mycosis fungoides. B hairy cell leukemia and mycosis fungoides occurring in the same patient seems to be a rare phenomenon with only 5 cases reported in the literature.

Entities:  

Keywords:  Cutaneous T-cell lymphoma; Hairy cell leukemia; Mycosis fungoides

Year:  2017        PMID: 28512405      PMCID: PMC5422730          DOI: 10.1159/000456650

Source DB:  PubMed          Journal:  Case Rep Dermatol        ISSN: 1662-6567


Introduction

Mycosis fungoides, the most common type of cutaneous T-cell lymphoma, can often be a difficult diagnosis that can have a protracted clinical course without definitive identification years after initial presentation. This disease accounts for about 50% of all primary cutaneous lymphomas [1]. B hairy cell leukemia is a chronic B-cell malignancy characteristically diagnosed by the presence of pancytopenia, splenomegaly, and “hairy cells” with a specific immunoprofile present in the blood, bone marrow, and other tissues [2]. This malignancy accounts for approximately 2% of all leukemias [2]. In general, mycosis fungoides and B hairy cell leukemia are both uncommon lymphoproliferative malignancies.

Case Report

A 65-year-old man was seen at the University Dermatology Clinic for a 9-month history of intensely pruritic red papules initially of the scalp and progressing to his face and rest of his body. The patient complained of generalized fatigue, severe pruritus, and night sweats causing an inability to maintain a job. He was previously treated empirically with oral antipruritic medications and topical corticosteroids with no improvement. Past medical history was significant for B hairy cell leukemia, hypertension, sleep apnea, gout, gastroesophageal reflux disease, a left knee replacement for osteoarthritis, and a clear cell renal cell carcinoma requiring a partial nephrectomy. Further history revealed no family history of skin cancers or hematological malignancies. A diagnosis of B hairy cell leukemia was made 3 years prior based on the presence of lymphocytosis (lymphocyte count of 9.5 × 109/L) with corresponding flow cytometry (positive for CD19, CD20, CD22, CD25, CD103, CD11c, FMC-7, CD79b, and SigM/D) and enlarged spleen (19 cm in size). The B cells accounted for 72% of the gated lymphoid cells and were monoclonal (λ-restricted). No coexpression of CD5 or CD10 was identified. The peripheral blood smear revealed a population of medium-sized lymphoid cells with monocytoid nuclei and moderate to abundant cytoplasm consistent with hairy cells. A bone marrow biopsy of the right iliac crest showed infiltration by small- to intermediate-sized lymphoid cells in a diffuse manner. These lymphoid cells had round nuclei with small nucleoli or clumped chromatin surrounded by empty spaces giving an appearance of a fried egg. Examination of the splenectomy specimen showed extensive infiltration of the splenic red pulp with the white pulp mostly depleted. On higher magnification, the nuclei of neoplastic cells were relatively vesicular and the nucleoli were often visible. These cells were positive for CD20 and BDA44 but negative for CD123 on immunohistochemistry. His hairy cell leukemia was treated with chemotherapy, specifically cladribine, and then rituximab (due to a poor response to the former), and a splenectomy with complete remission. On examination, he had multiple erythematous papules and pustules, many of which appeared to be follicular-based with secondary crusted excoriations. The lesions were widely distributed on his scalp, face, trunk, back as well as the upper and lower extremities (Fig. 1a). There was a cluster of patches coalescing into plaques noted on the left upper back.
Fig. 1

a Folliculotropic mycosis fungoides of the scalp (left) and left trunk (right). b Superficial perivascular and patchy lichenoid lymphocytic infiltrate is noted with associated epidermotropism. Hematoxylin and eosin. ×50. Upper back. c Lymphocytes show epidermotropism, aligning singly along the basal layer of epidermis. No spongiosis is noted. Hematoxylin and eosin. ×100. Upper back.

Biopsies of the scalp showed extensive solar elastosis of the papillary and reticular dermis with mild acanthosis and hyperkeratosis (mainly orthokeratosis with focal parakeratosis) overlying the epidermis. Pautrier microabscesses and epidermotropism were not noted. Dermal perifollicular infiltrates were predominantly formed by lymphocytes, which extended into the folliculosebaceous units with associated epithelial mucinosis. Eosinophils were noted within the infiltrate. Immunohistochemical stains were positive for CD2, CD3, and CD4 and negative for CD8 and CD20. Overall, these features were consistent with folliculotropic mycosis fungoides. Biopsies performed from the patches on the upper back disclosed mild to moderate superficial perivascular and patchy lichenoid infiltrate of lymphocytes (Fig. 1b). In foci, the lymphocytes showed epidermotropism and were aligned along the basal layer of the epidermis (Fig. 1c). Overall, the biopsies from the upper back area were consistent with patch-stage mycosis fungoides. T-cell gene rearrangement assays on the skin revealed a polyclonal pattern; however, T-cell gene rearrangement studies on peripheral blood revealed monoclonality. Flow cytometry showed that lymphocytes accounted for 44% of the total events with only 5% of the cells being B cells. The B cells were monotypic (λ) and immunophenotypic to the hairy cell leukemia variant, specifically CD103 and CD25 positive and CD5 negative. The T cells accounted for 77% of the total lymphoid cell population with a CD4:CD8 ratio of 1: 2.5. The T cells had a loss of CD26 in a subset of CD4-positive cells, which was suggestive of Sézary cells. Treatment with nbUVB phototherapy 3 times weekly to his entire body with clobetasol propionate spray occlusion to his scalp improved his symptoms and most of the lesions resolved within several months.

Discussion

A thorough review of the literature on PubMed, using the search terms (“mycosis fungoides” OR “cutaneous T-cell lymphoma”) AND (leukemia OR leukaemia OR lymphoma OR “lymphoid malignancy” OR “Hodgkin's disease” OR “non-Hodgkin's disease” OR “multiple myeloma” OR “B-cell”), identified 68 cases of concomitant mycosis fungoides and a lymphoid malignancy [2, 4, 5, 5, 6, 7, 8, 9, 10, 11, 12, 13, 14, 15, 16, 17, 18, 19, 20, 21, 22, 23, 24, 25, 26, 27]. Narrowing the results, we were able to find 5 cases of hairy cell leukemia along with mycosis fungoides reported [2, 5]. However, the possibility that both T- and B-cell malignancies occurring unrelated to one another in one patient is unlikely, as the incidence of each cutaneous and systemic neoplasm separately is very low [4, 6]. Therefore, the development of cutaneous T-cell lymphoma and hairy cell leukemia is a very rare phenomenon. A trend seen in various studies demonstrated that patients who develop primary cutaneous T-cell lymphoma are at an increased risk of developing a secondary malignancy [3, 4, 5, 28]. Amber et al. [28] confirmed this through examination of the Surveillance, Epidemiology, and End Results (SEER) database of the National Cancer Institute. Through evaluation of all cutaneous T-cell lymphoma cases between 1992 and 2011, there was an overall increased risk of secondary cancers, particularly within the first year of diagnosis [28]. Sidwell et al. [18] reported a patient with mycosis fungoides who subsequently developed Hodgkin disease, but analysis of cells from the skin and lymph nodes disproved the notion that these cancers were derived from a single cellular origin [18]. From studies performed by Vakeva et al. [3], they propose that these cancers may have a cancerogenic effect causing an increased risk of malignancies, in particular lymphomas. There is little to no evidence to support the reverse. Similarly there does not appear to be a common genetic mutation for hairy cell leukemia and mycosis fungoides. Although no consensus has been agreed upon, some authors suggest that a genetic predisposition for lymphoproliferative disease, an underlying viral infection, or possible mutagenic effects of cytostatic drugs as potential causes for developing concurrent B- and T-cell cancers [4]. Barzilai et al. [4] believe that alterations in progenitor stem cells prior to differentiation or production of cytokines by a first neoplasm stimulating the development of a secondary tumor can cause the development of B- and T-cell malignancies seen in one patient. Not only is the case exceedingly rare, it highlights the need to consider cutaneous T-cell lymphoma in patients with a nonspecific follicular eruption that is intensely pruritic disproportionate to the clinical findings and has failed to respond to conservative treatments.

Statement of Ethics

The patient provided consent for publication.

Disclosure Statement

The authors have no conflict of interest to declare.

Author Contributions

All authors contributed equally to the paper.
  25 in total

Review 1.  [Mycosis fungoides during B-cell lymphoma].

Authors:  J Castanet; J P Lacour; B Taillan; C Perrin; J G Fuzibet; J P Ortonne
Journal:  Ann Dermatol Venereol       Date:  1992       Impact factor: 0.777

2.  Coexistence of primary cutaneous anaplastic large cell lymphoma and mycosis fungoides in a patient with B-cell chronic lymphocytic leukaemia.

Authors:  M Marschalkó; J Csomor; N Eros; A Szigeti; J Hársing; J Szakonyi; M Désaknai; A Matolcsy; J Demeter; S Kárpáti
Journal:  Br J Dermatol       Date:  2007-10-10       Impact factor: 9.302

3.  Mycosis fungoides associated with B-cell malignancies.

Authors:  A Barzilai; H Trau; M David; M Feinmesser; R Bergman; D Shpiro; G Schiby; K Rosenblatt; R Or; E Hodak
Journal:  Br J Dermatol       Date:  2006-08       Impact factor: 9.302

4.  Mycosis fungoides and Hodgkin's disease.

Authors:  M Clement; H Bhakri; B Monk; K W Pettingale; A C Pembroke; A du Vivier
Journal:  J R Soc Med       Date:  1984-12       Impact factor: 5.344

5.  Mycosis fungoides and chronic lymphocytic leukaemia--composite T-cell and B-cell lymphomas presenting in the skin.

Authors:  P R Hull; A Saxena
Journal:  Br J Dermatol       Date:  2000-08       Impact factor: 9.302

6.  Co-existence of cutaneous T-cell lymphoma and B hairy cell leukemia.

Authors:  R Paolini; A Poletti; E Ramazzina; C Menin; M Santacatterina; M Montagna; L Bonaldi; A Del Mistro; S Zamboni; E D'Andrea
Journal:  Am J Hematol       Date:  2000-07       Impact factor: 10.047

7.  Mycosis fungoides and lymphoplasmacytoid immunocytoma in the same patient. A case report.

Authors:  M L Geerts; J Hamers; E W Schwarze; A Kint; H Roels; K Lennert
Journal:  Cancer       Date:  1984-11-15       Impact factor: 6.860

8.  Coincidence of B-cell chronic lymphocytic leukemia and cutaneous T-cell lymphoma (mycosis fungoides): immunologic characterization by monoclonal antibodies.

Authors:  K Sheibani; S J Forman; C D Winberg; H Rappaport
Journal:  Blood       Date:  1983-12       Impact factor: 22.113

9.  Review of contemporaneous mycosis fungoides and B-cell malignancy at Mayo Clinic.

Authors:  Elise Herro; David J Dicaudo; Mark D P Davis; Amy L Weaver; David L Swanson
Journal:  J Am Acad Dermatol       Date:  2009-05-28       Impact factor: 11.527

10.  Evidence for HTLV-I associated with mycosis fungoides and B-cell chronic lymphocytic leukemia.

Authors:  A Peterman; M Jerdan; S Staal; B Bender; H Striecher; J Schüpbach; L Resnick
Journal:  Arch Dermatol       Date:  1986-05
View more
  1 in total

Review 1.  Skin changes in hairy cell leukemia.

Authors:  Ewa Robak; Dorota Jesionek-Kupnicka; Tadeusz Robak
Journal:  Ann Hematol       Date:  2020-11-20       Impact factor: 3.673

  1 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.